| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/500 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Collagen alpha-3(VI) chain; CO6A3; |
| Entrez GeneID | 1293; |
| WB Predicted band size | 344kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from internal of human Collagen VI α3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于Collagen VI α3抗体的代表性文献信息，供参考：
---
1. **文献名称**：*Collagen VI regulates satellite cell self-renewal and muscle regeneration*
**作者**：Urciuolo A, et al.
**摘要**：该研究利用特异性Collagen VI α3抗体，揭示了其在调控肌肉干细胞微环境中的关键作用。实验表明，Collagen VI α3缺失会导致卫星细胞功能异常，影响肌肉再生能力(发表于*Nature Communications*, 2013)。
---
2. **文献名称**：*Antibody-based profiling of Collagen VI isoforms in fibrotic diseases*
**作者**：Gara SK, et al.
**摘要**：开发了针对Collagen VI α3链的单克隆抗体，并通过免疫组化和Western blot验证其特异性。研究发现该蛋白在皮肤纤维化和肿瘤基质中异常沉积，提示其作为疾病生物标志物的潜力(发表于*Matrix Biology*, 2018)。
---
3. **文献名称**：*Targeting Collagen VI α3 for Ullrich congenital muscular dystrophy therapy*
**作者**：Bonaldo P, et al.
**摘要**：通过患者来源的细胞模型，研究团队利用Collagen VI α3抗体验证了基因疗法对蛋白表达的恢复效果，证实其可改善细胞外基质结构异常，为先天性肌营养不良提供治疗方向(发表于*Science Translational Medicine*, 2016)。
---
**备注**：如需具体实验应用(如抗体货号、实验方法)，建议通过PubMed或抗体生产商官网(如Santa Cruz、Abcam)检索目标抗体的引用文献。
The Collagen VI α3 (COL6A3) antibody targets the α3 chain of collagen VI, a key extracellular matrix protein. Collagen VI is a heterotrimer composed of α1. α2. and α3 chains encoded by the *COL6A1*, *COL6A2*, and *COL6A3* genes, respectively. It forms a microfibrillar network that interacts with other matrix components and cells, providing structural support and regulating tissue homeostasis. The α3 chain, the largest subunit, contains unique domains critical for collagen VI assembly and function, including interactions with integrins and proteoglycans.
COL6A3 antibodies are widely used in research to study collagen VI expression, localization, and alterations in diseases. Mutations in *COL6A3* are linked to collagen VI-related disorders such as Ullrich congenital muscular dystrophy and Bethlem myopathy, characterized by muscle weakness, joint contractures, and skin abnormalities. These antibodies help identify reduced or abnormal collagen VI deposition in patient tissues or cell models.
In cancer research, COL6A3 antibodies have revealed upregulated collagen VI expression in tumor stroma, associated with metastasis and poor prognosis. Additionally, they are tools for exploring fibrosis, as collagen VI accumulates in fibrotic tissues like lungs, liver, and kidneys. Commercial COL6A3 antibodies are typically developed in hosts like rabbits or mice, validated for techniques including Western blotting, immunofluorescence, and immunohistochemistry. Understanding collagen VI α3’s role through these antibodies continues to advance insights into matrix biology and therapeutic targeting.
×
